Dolores Paredones
Acute Care · Los Angeles, CANPI 1225389224
Payments from drug & device makers
Across 274 payments — averaging $18.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$929
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$859
- AstraZeneca$698
- Lexicon Pharmaceuticals, Inc.$468
- Pfizer$303
- Boehringer Ingelheim$295
- plus $2K from 16 others
What the payments were for
- Food & beverage$5,06198%
- Education$1032%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 68 | $929 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 52 | $859 |
| AstraZeneca | 26 | $698 |
| Lexicon Pharmaceuticals, Inc. | 17 | $468 |
| Pfizer | 14 | $303 |
| Boehringer Ingelheim | 12 | $295 |
| Boston Scientific | 21 | $257 |
| Merck | 11 | $238 |
| Abbott | 9 | $190 |
| Amgen | 10 | $179 |
| Heartflow, Inc. | 7 | $133 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $125 |
| Medtronic | 4 | $90 |
| Johnson & Johnson | 4 | $85 |
| Bayer | 3 | $72 |
| Novo Nordisk | 3 | $65 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $60 |
| GSK | 2 | $49 |
| Lilly USA, LLC | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Atricure, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,163 in reported general payments places this provider in the 90th percentile of 1,153 acute care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 94 | $69,506 |
| EntrestoSacubitril/Valsartan | 77 | $68,143 |
| Metoprolol Succinate | 130 | $1,269 |
| Atorvastatin Calcium | 148 | $973 |
| Bumetanide | 13 | $775 |
| Midodrine Hcl | 16 | $699 |
| Amiodarone Hcl | 13 | $533 |
| Carvedilol | 91 | $485 |
| Furosemide | 89 | $361 |
| Amlodipine Besylate | 54 | $273 |
| Losartan Potassium | 43 | $267 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 30 | $265 |
| Hydralazine Hcl | 27 | $258 |
| ClopidogrelClopidogrel Bisulfate | 19 | $186 |
| Metoprolol Tartrate | 47 | $180 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $303 | $69,50694 claims |
| NovartisEntresto | $929 | $68,14377 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,153 acute care providers in California.
Other acute care in Los Angeles
- Frances DyLos Angeles$57K
- Kori Ann JohnstonLos Angeles$42K
- Sunita BoparaiLos Angeles$37K
- Sherona BauLos Angeles$32K
- Stacey GrossLos Angeles$22K
- Mary HuntsingerLos Angeles$12K
- Charlotte LipskyLos Angeles$10K
- Kimberly TranLos Angeles$8K
- Lisa YenLos Angeles$7K
- Rafael BegluyanLos Angeles$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.